SCHEMBL6091795

SCHEMBL6091795

COC(=O)c1ccc(C(=O)Cc2cc(-c3cccnc3)ccc2OC)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.59
CYP11B1 P15538 1/20 0.59
CYP11B2 P19099 1/20 0.59
SLC2A1 P11166 1/20 0.58
ABCB1 P08183 6/20 0.51
MKNK1 Q9BUB5 2/20 0.50
MKNK2 Q9HBH9 2/20 0.50
SMPD1 P17405 1/20 0.50
ACLY P53396 2/20 0.49
ALPL P05186 1/20 0.47
ABCC1 P33527 3/20 0.46
NR4A2 P43354 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
PTAFR P25105 1/20 0.45
KDR P35968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093061 0.90 MKNK1 (0.56) CYP19A1CYP11B1CYP11B2SLC2A1ABCB1
SCHEMBL2345607 0.79 CYP19A1 (0.74) CYP19A1CYP11B1CYP11B2SLC2A1MKNK1
SCHEMBL6092281 0.79 ALPL (0.50) MKNK2ALPLALDH1A1KDM4EMEN1
SCHEMBL6091489 0.77 HDAC1 (0.43) NR4A2KDM4EMEN1KMT2A
SCHEMBL6092548 0.76 KDM4E (0.50) NR4A2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL18355729 0.74 MKNK1 (0.76) CYP19A1CYP11B1CYP11B2SLC2A1ABCB1
SCHEMBL6094331 0.74 KMT2A (0.49) ALDH1A1KDM4EMEN1GAAKMT2A
SCHEMBL4509922 0.74 CYP11B2 (1.00) CYP19A1CYP11B1CYP11B2SLC2A1ABCB1
SCHEMBL11799106 0.74 ALDH1A1 (0.59) CYP19A1CYP11B1CYP11B2SLC2A1ALDH1A1
SCHEMBL1399775 0.74 CYP19A1 (0.74) CYP19A1CYP11B1CYP11B2SLC2A1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 CYP19A1 260/4885CYP11B1 23/4885CYP11B2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.